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Abstract
Objective: Type 2 diabetes is the main cause of end-stage renal disease (ESRD) in Europe and the USA. Angiotensin-
converting enzyme (ACE) inhibitors have a potential to slow down the progression of renal disease and therefore provide a
renal-protective effect. The aim of our study was to assess the most cost-effective time to start an ACE inhibitor (or an
angiotensin II receptor blocker [ARB] if coughing as a side effect occurs) in patients with newly diagnosed type 2 diabetes in
The Netherlands.
Methods: A lifetime Markov decision model with simulated 50-year-old patients with newly diagnosed diabetes mellitus
was developed using published data on costs and health outcomes and simulating the progression of renal disease. A
health insurance perspective was adopted. Three strategies were compared: treating all patients at the time of diagnosing
type 2 diabetes, screening for microalbuminuria, and screening for macroalbuminuria.
Results: In the base-case analysis, the treat-all strategy is associated with the lowest costs and highest benefit and therefore
dominates screening both for macroalbuminuria and microalbuminuria. A multivariate sensitivity analysis shows that the
probability of savings is 70%.
Conclusions: In The Netherlands for patients with type 2 diabetes prescription of an ACE inhibitor immediately after
diagnosis should be considered if they do not have contraindications. An ARB should be considered for those patients
developing a dry cough under ACE inhibitor therapy. The potential for cost savings would be even larger if the prevention
of cardiovascular events were considered.
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Introduction
The prevalence of type 2 diabetes and its secondary complica-
tions will rise [1–3] due to ageing population and growing obesity.
This type of diabetes represents the most common form of
carbohydrate disorders affecting at least 5% of the population in
the industrialized world [4]. As a result higher costs for diabetes
treatment in general and especially treatment of secondary
complications will be a huge burden for health care systems.
Type 2 diabetes is the main cause of end-stage renal disease
(ESRD) in the Netherlands [5] as well as in other European
countries and the United States [6–7]. Diabetic nephropathy leads
to a gradual decline of the renal function and is initially
characterized by micro- or macroalbuminuria. Diabetic nephrop-
athy may progress to ESRD, which is defined by the need for
either long-term dialysis or renal transplantation [8]. The
prevalence of patients in renal replacement therapy in the
Netherlands doubled within the last 15 years [9]. In 2010, about
15 000 patients underwent renal-replacement therapy. In the last
five years, the proportion of transplanted patients has been
continuously increasing and represents about 57% of all patients
requiring renal replacement therapy [9].
The costs of ESRD treatment are rather high, with a share of
the national expenditures in European countries ranging from
0.7% in the UK to 1.8% in Belgium [10,11], with a share in the
Netherlands of about 1.3%. In the Netherlands, the costs of ESRD
treatment amount to J42 000 per patient per year [10,12,13].
Hence, prevention of ESRD is not only important from a medical,
but also from an economic viewpoint.
Angiotensin converting enzyme (ACE) inhibitors slow down the
progression of diabetic nephropathy independent of an elevated
blood pressure [14,15]. Angiotensin receptor blockers (ARBs) have
similar effects on renal outcomes in diabetic patients [16] but are
more expensive, mostly due to patent protection. Evidence
suggests that the only major clinical difference between these
classes of drugs is a higher risk of dry cough associated with ACE
inhibitors [17].
Several national and international clinical practice guidelines
recommend starting ACE inhibitor therapy in diabetic patients
with (micro)albuminuria [18-20]. However, physician compliance
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rather low [21]. Cost-effectiveness models conducted in the United
States by Golan et al. (1999) [22], Rosen et al. (2005) [23] and in
Germany by Adarkwah et al. (2010) [24] suggest that the best
starting point for ACE inhibitor therapy is immediately after
diagnosis of diabetes. For the Netherlands no data are available on
the cost-effectiveness of ACE inhibitor therapy in diabetic patients
with (micro)albuminuria. However, results of the non-Dutch
studies may not be transferable to the Netherlands. Transferability
of economic evaluation studies between countries is hindered by a
number of factors such as demography, the epidemiology of the
disease, availability of health care resources and differences in
reimbursement systems between countries, in particularly due to
variances in absolute and relative costs/prices.
The goal of this study is to present a cost-effectiveness model,
which determines the best time to start an ACE inhibitor in newly
diagnosed patients with type 2 diabetes and without hypertension
or heart failure in the Netherlands. The analysis is conducted from
a health care perspective in order to increase comparability to
other models on this topic [22-24]. In our model we included
ARBs as an alternative for patients who experience ACE-
inhibitor-induced cough. In the base case the age of 50 years
was assumed as the mean age of diagnosing type 2 diabetes
[25,26].
Methods
Overview and Model Design
Is it cost-effective to treat all newly diagnosed type 2 diabetic
patients in the Netherlands with an ACE inhibitor to prevent renal
disease? We conducted a cost-utility analysis and measured health
outcomes in terms of quality-adjusted life years (QALYs). We
adapted a Markov decision model previously developed for the
German setting [24] and also proven applicable for non-diabetic
advanced renal disease [27] in order to simulate the course of a
cohort of 1 000 patients at the age of 50 years as it progresses to
microalbuminuria, macroalbuminuria, ESRD, and death. A
Markov model is an iterative process where patients are assumed
to stay in one cycle (i.e., a defined health state) for a certain time
and then make a transition to another cycle. Markov models are
useful when a decision problem involves risk that is continuous
over time, when the timing of events is important, and when
important events may happen more than once. The model was
built in Microsoft ExcelH 2007. We chose a cycle length of one
year for the health states defined by the Markov model because all
transition probabilities gathered from the literature referred to a
duration of at least one year. All input data included in the model
can be found in table 1. Our Markov model contains the following
five health states (Figure 1), which represent the occurrence of
events after model entry:
1. type 2 diabetes, with normoalbuminuria (excretion , 30 mg/
d)
2. type 2 diabetes, with microalbuminuria (excretion 30–300 mg/
d)
3. type 2 diabetes, with macroalbuminuria (excretion .300 mg/
d)
4. ESRD (treated with dialysis or renal transplantation)
5. death
We assumed that diabetic nephropathy progresses without
skipping any stage. Further, patients may die at any time (stage 5).
The states of albuminuria were defined according to the
recommendations of the American diabetes Association [20].
During each cycle, patients accumulate utility (measured by
QALYs) and costs. A half-cycle correction was applied to both
costs and outcomes to allow for transition events occurring mid-
way through each 12-month cycle.
The simulation was done until the age of 99. Hence, the time
horizon is 50 years. The age of 99 was chosen as a cutting point as
there are no mortality data available beyond this age. Regardless,
more than 99% of patients in the simulation are dead at this age.
Clinical Strategies
Three starting points for ACE inhibitors were considered [3,22].
In the ‘‘screen for microalbuminuria’’ strategy patients are
screened for microalbuminuria once a year and treatment is
started if the test result is positive. In the ‘‘screen for
macroalbuminuria’’ strategy patients are screened for macroalbu-
minuria once a year and treatment is also started if the test result is
positive. In the ‘‘treat all’’ strategy no screening is performed at all
and patients start on ACE inhibitor therapy at the time of
diagnosing type 2 diabetes. In addition, the analysis performed
included the ARB option for the entire patient population in all
three strategies reflecting a more expensive treatment. To find
information on the distribution of health states at the time of
diagnosis, we used the following search strategy in the PubMed
database (date: February 08, 2011): (newly diagnosed[All Fields]) AND
macroalbuminuria[All Fields] AND microalbuminuria[All Fields] AND
prevalence[All Fields] AND (albumin excretion [All Fields]) NOT (type 1
diabetes [All Fields]). We obtained 2 hits. Thereof one study was
excluded because it was conducted among Pima Indians. The
other one is a Finnish prospective observational study [28], which
was conducted from 1982 to 1992. In this study, the distribution of
health states at the time of diagnosis (average age: 58 years) was as
follows: 79% normoalbuminuria, 18% microalbuminuria, and 3%
macroalbuminuria. We tested the impact of the initial distribution
on results in a sensitivity analysis.
Transition Probabilities
In order to identify studies on the effectiveness of ACE inhibitor
or ARB therapy on the prevention of diabetic kidney disease we
searched in the Cochrane Database of Systematic Reviews using
the search strategy normoalbuminuria OR microalbuminuria OR
macroalbuminuria. We found two meta-analyses proving evidence
that ACE inhibitors halt the transition from normo- to
microalbuminuria and micro- to macroalbuminuria [29,30].
These meta-analyses pooled studies on patients with type 1 and
type 2 diabetes, as heterogeneity did not appear to an issue.
Compared to placebo, ACE inhibitors significantly reduced the
development of microalbuminuria (six trials, 3 840 patients:
relative risk (RR) 0.60, 95% confidence interval (CI) 0.43 to 0.84),
and the progression from microalbuminuria to macroalbuminuria
(17 trials, 2 036 patients: RR 0.45, 95% CI 0.29 to 0.69).
In order to identify studies on the effectiveness of ACE
inhibitors or ARBs on the transition from macroalbuminuria to
ESRD, evidence-based clinical practice guidelines were checked
on the prevention of diabetic nephropathy [19,31–33]. One
randomized clinical trial [15] was identified that was rated as well-
designed randomized controlled trial (RCT) [19,33] providing
high-grade evidence. In this trial captopril significantly reduced
the development of ESRD compared to placebo (409 patients, RR
0.61, 95% CI 0.50 to 0.75).
To determine annual transition probabilities we first calculated
a total probability for each arm, by dividing the number of events
(ESRD) during the trial period by the number of patients. Next,
we determined annual transition probabilities by assuming a
Cost-Effectiveness of ACE Inhibitors
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constant hazard rate yields an exponential survival curve.
In patients with normo-, micro-, and macroalbuminuria
mortality is a function of age and was calculated by multiplying
age-specific mortality rates of the Dutch general population [35]
with a standardized mortality ratio for patients with diabetes
compared to the general population [1,36]. For patients with
normo-, micro-, and macroalbuminuria we assumed that mortality
Table 1. Data used to determine the cost-effectiveness of ACE inhibitors and ARBs in newly diagnosed type 2 diabetes.
Variable Base-case estimateRange tested* Reference
Initial disease prevalence, %
Normoalbuminuria 79 66.5–100 [28]
Microalbuminuria 18 0–27.6 [28]
Macroalbuminuria 3 0–5.9 [28]
Annual transition probabilities (without ACE inhibitors)
Normoalbuminuria to microalbuminuria 0.056 0.03–0.08 [29]
Microalbuminuria to macroalbuminuria 0.094 -0.02–0.20 [30]
Macroalbuminuria to ESRD 0.056 0.025–0.08 [15]
Normo-/micro-/macro-
albuminuria to death
Age-dependent – [35]
ESRD to death 0.09 – [9]
Relative risk for progression with ACE inhibitors
Normoalbuminuria to microalbuminuria 0.60 0.43–0.84 [29]
Microalbuminuria to macroalbuminuria 0.45 0.29–0.69 [30]
Macroalbuminuria to ESRD 0.61 0.50–0.75 [15]
Utilities (health states)
Diabetes (baseline health) 0.88 0.86–0.90 [38]
ESRD 0.62 0.39–0.84 [39]
ACE inhibitor/ARB treatment 1.00 0.95–1.00 [63]
Annual costs, J
General health care expenditures 3.310,23 -
23.626,23 (age-
dependent)
– [43,44,55]
Per-patient cost of diabetes compared to non-diabetic population 547 – [43,44,55]
applied to all health states except for ESRD
ACE inhibitor (20mg enalapril daily) 6.96 – [46]
applied to all health states except for ESRD
ARB (300mg irbesartan daily) 298.68 – [46,47]
applied to all health states except for ESRD
Mixed drug therapy costs (9.9% treated with ARBs) 62.70 62.70–83.78 [46]
applied to all health states except for ESRD
Screening for microalbuminuria 7.00 – [58,59]
Screening for macroalbuminuria 1.12 – [58,59]
ESRD 42 110 33 688–50 532 [9,13]
Transplantation 14 387 – [9,13]
Dialysis 79 112 – [9,13]
Home/in-center hemodialysis 83 217 – [9,13]
Continuous ambulatory
peritoneal dialysis
54 067 – [9,13]
Continuous cycling
peritoneal dialysis
69 546 – [9,13]
SMR 1.41 1.39–1.43 [1]
Rate of ARB use, % 9.9 9.6–10.2 [17]
Specificity of HPLC (microalbuminuria screening procedure) 1.00 0.81–1.00 [53]
Discount rate of costs 0.04 0.00–0.10 [44,54,55];
Discount rate of benefits 0.015 0.00–0.10 [44,54,55];
ACE = angiotensin-converting enzyme; ARB = angiotensin II receptor blocker; ESRD = end-stage renal disease; HPLC = high performance liquid chromatography;
SMR = standardized mortality ratio.
doi:10.1371/journal.pone.0026139.t001
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significant difference exists. For patients with ESRD, we calculated
the annual mortality rate based on 13 905 patients in the
Netherlands [9], by dividing the annual number of decedents by
the total number of patients. While the annual number of
decedents treated with dialysis could be derived from the website,
the number of decedents with a transplant was obtained by
personal communication (A. Hemke, Dutch End-Stage Renal
Disease Registry, March 17, 2011).
Preference Weights
We included preference weights of diabetic patients (table 1) from
a published cross-sectional study [37]. Adult diabetic patients (n =
292) with a disease duration of at least one year and a mean age of
62 years (range 21–85) were interviewed by the time trade-off
(TTO) method. We assumed that patients with normo-, micro-, or
macroalbuminuria do not suffer from an additional reduction in
health-relatedqualityoflife[38].Thereisnoconvincingevidencein
the literature that confirms a utility decrease merely due to
albuminuria. The preference weight for ESRD was taken from a
systematic review of empirical studies in which TTO weights were
provided by patients [39]. The TTO is the most commonly used
method to elicit quality-of-life weights for QALYs [40,41]. The
TTOtechnique determines the proportion ofremaininglife yearsin
poor health patients are willing to give up or trade in exchange for
perfect health. Based on patient responses utility scores are
calculated. Utility measures in economic evaluations are becoming
increasingly important given the fact that decision makers are asked
to optimize the allocation of scarce health care resources across
disease areas and patient groups [42]. Values are similar to EQ-5D
scores (baseline value 0.61) reported by de Wit et al. (1998) [13].
Costs
As stated, the analysis is conducted from the health care
perspective. Hence, only direct costs and direct health effects –
defined as life years gained – were considered. Costs were inflated
to year 2010 euros using data on the consumer price index [43].
Costs of ACE inhibitors, ARBs, annual screening procedures, and
treatment for ESRD as well as health care expenditures related
and unrelated to diabetes were taken into account. The
recommendations of the Dutch guidelines for pharmacoeconomic
research were followed [44]. For ACE inhibitor therapy the most
frequently prescribed ACE inhibitor in the Netherlands, enalapril,
[45] was taken into consideration. In the base case, the cheapest
generic of enalapril 10 mg daily was used, whereas the most
expensive one was applied in the sensitivity analysis [46]. For
ARBs we considered a dose of 300 mg irbesartan daily [46], which
is more effective in renal protection than a dose of 150 mg [47].
The costs of enalapril and irbesartan treatment were based on
2011 Dutch prices and include 6% value-added tax as well as a 3-
monthly pharmacists’ prescription fee of J7.50 [48]. As
recommended by a published health technology assessment
(HTA) report [49] and a national clinical chemistry report [50],
a quantitative screening test for microalbuminuria (high perfor-
mance liquid chromatography or immunoturbidimetrie) was
preferred over a semi quantitative one (e.g., Micral-TestH)
[51,52], because it demonstrates higher sensitivity (100%) [52]
and specificity (81-98%) [53]. Bakker et al. [51] clearly state that a
simple dipstick test is not sufficient to detect microalbuminuria at
an early stage. In the base-case analysis we assumed a specificity of
100% which is conservative because treating false positives (i.e.,
patients with normoalbuminuria) leads to cost savings. In the
sensitivity analysis we applied a specificity of 81%. To screen for
macroalbuminuria we used a dipstick test applied in a general
practitioner’s office recommended by the Dutch Kidney Check
Campaign [31,49].
The annual costs of patients with ESRD were calculated as a
weighted average of the costs of different types of dialysis as well as
renal transplantation based on a Dutch study [13] and prevalence
data available from the national register [9].
In detail, the following calculations were made (see table 2 in the
appendix for details):
1) cost of dialysis = b1x1 + b2x2 + b3x3 = X, where xn =
annual cost of dialysis treatment n=1,2,3; bn = prevalence
weight of the dialysis treatment, and b1 + b2 + b3 =1
2) cost of ESRD = pX + (1-p)Y, where Y = cost of renal
transplantation and p = proportion of ESRD treated by
dialysis treatment.
A transplant survival of 10 years was assumed and a distinction
made between the first year of transplantation and the years
following. Costs were inflated to 2010 Dutch prices.
Health care expenditures related and unrelated to diabetes were
both included. Costs were discounted at an annual rate of 4%
whereas benefits were discounted at an annual rate of 1.5% in
accordance with the CVZ recommendations [44,54,55].
Sensitivity Analyses
To address uncertainty around mean incremental costs and
effectiveness, univariate sensitivity analyses were conducted.
Figure 1. Schematic representation of the Markov decision model.
doi:10.1371/journal.pone.0026139.g001
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bound of the 95% CI of the mean.
In order to assess how a simultaneous change of several
variables affects the incremental cost-effectiveness ratio (ICER), we
performed a Monte Carlo simulation, a type of multivariate
sensitivity analysis. This technique runs a large number of
simulations (here: 1 000) by repeatedly drawing samples from
probability distributions of input variables. Thus, it provides a
probability distribution for the output variables, i.e., incremental
costs and effectiveness. Probabilities and relative risks were
assumed to follow a beta distribution Beta(a, b) because they are
restricted to take on values between 0 and 1. Because the
distribution of health states at the time of diagnosis had more than
2 outcomes, we assumed a Dirichlet distribution Dirichlet(a1, a2,
... ,ak) [37]. Cost data were assumed to follow a gamma
distribution Gamma(a, b) because they are normally distributed
but restricted to take on values between 0 and 1. The standard
deviation of probabilities and relative risks was calculated
according to the following formula [56]:
s~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
p(1-p)
n
r
Given the ambiguous interpretation of negative ICERs, we
transformed ICERs into net monetary benefits (NMBs). We
generated a cost-effectiveness acceptability curve based on the
distribution of NMBs for each value of the willingness to pay per
QALY gained. A cost-effectiveness acceptability curve allows a
decision maker to consider whether a prevention strategy is cost-
effective in relation to the maximum amount a decision-maker is
willing to pay for a QALY. At each ceiling value for the willingness
to pay for a QALY, the cost-effectiveness acceptability curve shows
the probability that treatment is cost-effective. The input data for
the model are summarized in table 1.
Results
Base-case Analysis
The base-case analysis, which applies to 50-year-old patients,
shows that ‘‘no screening and treatment’’, ‘‘screening for
macroalbuminuria’’, and ‘‘screening for microalbuminuria’’ are
all dominated by the ‘‘treat all’’ strategy, which is associated with
the lowest costs and highest benefit (table 3). Again, the ‘‘treat all’’
strategy implies that all patients are treated with an ACE inhibitor
(or an ARB in the event of cough).
Sensitivity Analysis
In the univariate sensitivity analysis, variables with the largest
impact on incremental costs and effectiveness are the absolute risk
for progression from micro- to macroalbuminuria without ACE
inhibition as well as the relative risk for progression from normo-
to microalbuminuria with ACE inhibitor therapy and the discount
rate (see table 4 for details). When assuming a low progression rate
from micro- to macroalbuminuria without ACE inhibition,
screening for microalbuminuria dominates the ‘‘treat all’’ strategy.
A threshold sensitivity analysis shows that at an annual drug cost of
J426.70 (base case: J62.70) the breakeven point is reached. The
probability of savings is 70%.
Figure 2 shows the cost-effectiveness acceptability curve, which
considers uncertainty in cost-effectiveness. The probability of
savings of the ‘‘treat all’’ strategy compared to screening for
microalbuminuria is 70% (see also figure 3 for the scatterplot).
Discussion
This modeling study shows that treating all patients with type 2
diabetes with ACE inhibitors (and more expensive ARBs in the
event of cough) immediately after diagnosis is cost-effective and
even reduces health care expenditures in the Dutch setting. The
results were robust to a variety of different assumptions of
uncertainty.
Although a significant number of newly diagnosed type 2
patients may receive blood pressure medications, there is no
evidence to date that these patients are primarily prescribed an
ACE inhibitor, which underlines the significance of this analysis.
Still, our model is far from being perfect, but in modeling studies
this is rarely the case due to constraints of resources, time, and
information availability.
Table 2. Parameters used for calculating the cost of end-
stage renal disease (see cost section under ‘‘Methods’’).
variable meaning
1 home/center hemodialysis
2 continuous ambulatory peritoneal dialysis (CAPD)
3 continuous cycling peritoneal dialysis (CCPD
b1 0.82
b2 0.106
b3 0.074
x1 J 83 217
x2 J 54 067
x3 J 69 546
p 0.43
X J 79 112
Y J 14 387
doi:10.1371/journal.pone.0026139.t002
Table 3. Results of the base-case analysis, based on mean estimates of input variables.
Strategy Costs (J) Undiscounted LYs Discounted QALYs ICER (J/QALY)
Screening for macroalbuminuria 110 777 28.52 19.15 dominated
Screening for microalbuminuria 101 140 28.88 19.54 dominated
Treating all patients with ACEIs/ARBs 98 421 28.94 19.63 dominant
ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; LYs = life years; QALY = quality-adjusted life-years; ICER = incremental cost-
effectiveness ratio.
doi:10.1371/journal.pone.0026139.t003
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treating all patients with ACE inhibitors vs screening for microalbuminuria (reference strategy).
Incremental costs Incremental QALYs
Incremental cost-
effectiveness ratio
Initial disease prevalence: Proportion of normoalbuminuric patients, %
Lower bound 22 289 0.080 228 647
Higher bound 23 442 0.120 228 647
Annual transition probabilities (without ACE inhibitors)
from normo- to microalbuminuria
Lower bound -1 712 0.062 227 659
Higher bound 23 348 0.123 227 214
from micro- to macroalbuminuria
Lower bound 1 238 -0.22 257 155
Higher bound 24 604 0.166 227 736
from macroalbuminuria to ESRD
Lower bound 21 202 0.047 225 823
Higher bound 23 625 0.126 228 661
Relative risk for progression with ACE inhibitors
from normo- to microalbuminuria
Lower bound 24 352 0.141 230 831
Higher bound 2734 0.036 220 510
from micro- to macroalbuminuria
Lower bound 21 836 0.066 227 921
Higher bound 2 3 730 0.131 -28 403
from macroalbuminuria to ESRD
Lower bound 22 274 0.080 -28 358
Higher bound 23 229 0.112 228 727
Utilities (health states)
Diabetes (baseline health)
Lower bound 22 719 0.090 230 264
Higher bound 22 719 0.100 227 194
ESRD
Lower bound 22 719 0.142 219 081
Higher bound 22 719 0.049 255 041
Disutility of ACE inhibitor treatment
Lower bound 22 719 0.092 229 554
Higher bound 22 719 0.095 228 647
Costs
ACE inhibitor
Lower bound 22 719 0.095 228 647
Higher bound 22 569 0.095 -27 062
ESRD
Lower bound 21 858 0.095 219 581
Higher bound 23 579 0.095 237 713
SMR
Lower bound 22 723 0.096 228 249
Higher bound 22 715 0.093 229 046
Rate of ARB use
Lower bound 22 419 0.095 225 463
Higher bound 22 854 0.095 230 042
Specificity of HPLC (microalbuminuria screening procedure)
81% 2 1 853 0.039 247 513
Cost-Effectiveness of ACE Inhibitors
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with ACE inhibitors may even be underestimated for several
reasons. First, we did not model that ACE inhibitors and ARBs
reduce the risk for cardiovascular events [57], which would lead to
additional savings. Second, Second, we did not consider real-world
compliance with ACE inhibitor therapy due to a lack of data. In
the real world some patients discontinue ACE inhibitor therapy
and thus do not incur any drug cost. On the other hand, the model
considered trial-based compliance on the effect side, as the rate of
compliance is implicitly incorporated in clinical trial results, i.e.,
efficacy data refer both to adherers and non-adherers. For this
reason the Markov model includes patients who discontinue ACE
inhibitor treatment in the ACE inhibitor arm.
Third, the screening costs considered for microalbuminuria
screening are based on one annual test only. In contrast,
considering recommended screening procedures from the PRE-
VEND IT study [58,59] as a basis would lead to a fundamental
increase of screening costs as a spot-urine sample (either the first-
Incremental costs Incremental QALYs
Incremental cost-
effectiveness ratio
Discount rate of costs
0% 29 179 0.095 296 710
1.5% 25 708 0.095 260 140
4% 22 719 0.095 228 647
7% 21 189 0.095 212 523
10% 2537 0.095 256 5 5
Discount rate of effects
0% 22 719 0.139 219 592
1,5% 22 719 0.095 228 647
4% 22 719 0.051 252 850
7% 22 719 0.026 2105 670
10% 22 719 0.014 2200 909
QALYs = quality-adjusted life years; ACE = angiotensin-converting enzyme; ESRD = end-stage renal disease;
SMR = standardized mortality ratio; HPLC = high performance liquid chromatography
‘‘Lower bound’’ and ‘‘higher bound’’ refer to the limits of the 95% confidence interval.
doi:10.1371/journal.pone.0026139.t004
Table 4. Cont.
Figure 2. Cost-effectiveness acceptability curve.
doi:10.1371/journal.pone.0026139.g002
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used as a pre-screening. Patients whose urine is tested positive
should have their 24-h urine samples tested repeatedly afterwards
[60].
Forth, as this study is based on a cohort simulation it uses data
on the population mean. In contrast, a patient-level simulation
would account for the fact that some individuals may stay in more
than 2 stages in a year, although this is rarely the case. In any case,
if patients progressed more rapidly (had higher risk), then ACE
inhibitor treatment could lead to an even larger absolute risk
reduction and therefore larger savings.
Finally, costs of dialysis treatment will likely continue to rise in
the future, thus increasing the potential for savings by preventing
ESRD. Dialysis costs have increased within the last years [12] and
we expect this trend to continue due to stricter regulations
concerning dialysis safety, technological advancement of dialysis
machines, and better-tolerated dialysis solutions. Further limita-
tions of the model relate to the data sources.
First, the model uses some epidemiological data from Western
countries other than the Netherlands. For example, we used a
Finnish study [28] as the source of the distribution of health states
at the time of diagnosis. However, changing the initial distribution
of health states had little impact on the outcome.
Second, transition rates from macroalbuminuria to ESRD with
and without ACE inhibitors were not available for patients with
type 2 diabetes. Therefore, we used a randomized controlled trial
in patients with type 1 diabetes as the source [15].
Third, the standardized mortality ratio (SMR) we applied to
diabetic patients without ESRD [1] includes patients with ESRD.
Excluding these patients would lower the SMR to a minor degree
as less than 2% of the Dutch diabetic population receives renal
replacement therapy [35].
Forth, we assumed that the SMR is the same for patients with
normo-, micro-, and macroalbuminuria as there are no valid data
showing that a significant difference exists. The slightly higher
mortality ratio in microalbuminuric patients in the HOPE study
(2000) [57] was most likely the result of prior cardiovascular
events. There is no evidence in the literature that mortality rates
increase only on the basis of the level of albumin in the urine. This
is the same with the utilities, which are assumed to do not differ
between different stages of albuminuria.
Finally, having microalbuminuria or macroalbuminuria might
cause disutility due to anxiety. However, standard preference
measures such as the SG or the TTO method are not able to
capture anxiety over future events as both evaluation methods
assume a constant health state over the remaining period of life.
Compared to previous cost-effectiveness models, which were
conducted by Golan et al. (1999) [22] and Rosen et al. (2005) [23]
based on U. S. data, a much broader evidence base for the
transition between normo- to microalbuminuria and micro- to
macroalbuminuria was included in the present study. In addition,
we considered that patients who are noncompliant with ACE
inhibitors due to cough may receive more expensive ARBs, as
similarly done for the German setting [24]. The fact that a small
proportion of patients on ARBs (3.2%) also develop cough [17]
and thus may discontinue treatment was disregarded. The reason
for the exclusion is that noncompliance with treatment is already
incorporated in the relative risk of treatment (thus lowering the
relative risk), as in RCTs a certain proportion of patients
discontinued treatment. In contrast to the previous models
mentioned above we additionally conducted the analysis including
an ARB for the entire patient population in need of treatment.
This was done as some studies question that ARBs are not only a
more expensive, but also a more effective alternative compared to
Figure 3. Cost-effectiveness plane showing 1000 replications from a distribution of cost and quality-adjusted life year (QALY)
differences (angiotensin converting enzyme inhibitor vs microalbuminuria screening).
doi:10.1371/journal.pone.0026139.g003
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treatment costs of the ARB therapy this strategy must be
considered cost-effective. However, we assumed equal effective-
ness of all ACE inhibitors and ARBs, as meta-analyses do not
suggest any independent effect of single renin-angiotensin-system
agents [61,30]. For instance, an ARB as an equivalent but more
expensive alternative should only be prescribed in case of a
contraindication (e.g. dry cough associated with ACE inhibitor
treatment).
Still, similar to Adarkwah et al. (2010) [24] our model shows
that treating all newly diagnosed type 2 diabetic patients with ACE
inhibitors saves costs. The probability of savings is higher in
Germany than in the Netherlands (89% vs. 70%). Reasons for this
difference are not obvious as, e.g., costs of screening, ACE
inhibitor treatment, and ESRD are quite similar. In contrast to
Rosen et al. (2005) [23], we did not consider the preventive effect
of ACE inhibitors on cardiovascular outcomes, which would have
increased savings. An important reason for the large savings
potential in the Netherlands is the low price of enalapril, which has
substantially decreased during the last few years [46,62]. The most
ARBs are still protected by patent. Irbesartan, which we included
in our study, is protected until March 2012. Assuming that prices
of ARBs will decline after expiration of the patent protection
would further strengthen our conclusion.
For patients with type 2 diabetes treatment with an ACE
inhibitor to prevent the occurrence or progression of diabetic
kidney disease is highly cost-effective. Current national guidelines,
which do not even consistently recommend an ACE inhibitor for
patients with microalbuminuria need to be reconsidered. Still, it is
unclear whether a societal perspective leads to smaller or larger
savings than a health care perspective. For instance, ACE inhibitor
treatment avoids productivity loss due to renal failure and
copayments for the treatment of renal failure, but drug copay-
ments lead to additional costs.
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